Christopher Richard Anzalone sold $1.5M of ARWR
Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC.. 141,122 shares at an average of $10.87, traded Apr 9, 2025, filed Apr 11, 2025.
Score components
- +25RoleCEO
- +25Trade size$1.5M at market
- 0Share of holdings soldSold 3.5% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +10.5%, 3m +55.3%, 6m +200.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-017592, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 9, 2025 | SOpen-market sale Common Stock | -35,305 | $9.93 | $351k | 4,027,072 | Apr 11, 2025 |
| Apr 9, 2025 | SOpen-market sale Common Stock | -3,400 | $10.75 | $37k | 4,023,672 | Apr 11, 2025 |
| Apr 9, 2025 | SOpen-market sale Common Stock | -1,617 | $11.76 | $19k | 4,022,055 | Apr 11, 2025 |
| Apr 10, 2025 | SOpen-market sale Common Stock | -50,000 | $10.87 | $544k | 3,972,055 | Apr 11, 2025 |
| Apr 11, 2025 | SOpen-market sale Common Stock | -50,800 | $11.49 | $584k | 3,921,255 | Apr 11, 2025 |
Related signals
Other insiders at ARROWHEAD PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 8Weak | ARROWHEAD PHARMACEUTICALS, INC. | Hongbo Lu director | $228k 2,970 shares | -5% | |
| 34Weak | ARROWHEAD PHARMACEUTICALS, INC. | Daniel Joseph Apel Chief Financial Officer | $934k 13,095 shares | -7% | |
| 25Weak | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $750k 10,000 shares | -4% | |
| 15Weak | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $642k 10,000 shares | -4% | |
| 43Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $872k 13,187 shares | -0% | |
| 40Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Patrick O'Brien COO | $3.1M 49,493 shares | -9% | |
| 40Moderate | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $2.5M 40,164 shares | -19% | |
| 30Weak | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $3.6M 51,726 shares | -1% | |
| 28Weak | ARROWHEAD PHARMACEUTICALS, INC. | Mauro Ferrari director | $527k 7,530 shares | -10% | |
| 35Weak | ARROWHEAD PHARMACEUTICALS, INC. | Adeoye Y Olukotun director | $677k 10,000 shares | -23% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.